Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Skeletal Radiology
Published in: Skeletal Radiology 1/2012

01-01-2012 | Scientific Article

Atypical diaphyseal femoral fractures—new aspects

Author: Frieda Feldman

Published in: Skeletal Radiology | Issue 1/2012

Login to get access

Abstract

Post menopausal osteoporotic fractures are a major public health concern worldwide with oral bisphosphonates favored for their prevention and treatment. Recent interest has centered on clinically observed, unusually sited femoral diaphyseal fractures, particularly attributed to alendronate. Their imaging presentations on routine radiographs, alternate imaging modalities, and associated pitfalls in nine fractures in six patients are selectively illustrated by seven fractures in four patients that serve to emphasize the following: (1) Bisphosphonates other than alendronate have been used for treating various bone diseases in children and men as well as osteoporotic women. (2) Effects may differ with each bisphosphonate’s route of administration and prolongation of activity, despite discontinuation. Prior investigations and theoretical mechanisms of bisphosphonates as a class rather than with a specific alendronate association are reviewed to provide a broader basis for evaluating their recently observed clinical and radiographic complications.
Literature
1.
Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.PubMedCrossRef
2.
Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118–24.PubMedCrossRef
3.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.PubMedCrossRef
4.
Bilezikian JP. Efficiency of bisphosphonates in reducing fracture risk in post menopausal osteoporosis. Am J Med. 2009;122:S14–21.PubMedCrossRef
5.
Tomino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7 year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000;85:3109–15.CrossRef
6.
Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone. 2003;33:301–7.PubMedCrossRef
7.
La Velle DG. Fractures of the hip. In: Canale ST, editor. Campbell’s operative orthopaedics, vol. 3, 10th ed. St. Louis: Mosby 2002:2873–938.
8.
Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009;80(4):413–5.PubMedCrossRef
9.
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med. 2007;357:2028–39.PubMedCrossRef
10.
Goh SK, Yang KY, Koh JSB, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89B:349–53.
11.
Kwek EB, Goh SK, Bee Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224–31.PubMedCrossRef
12.
Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948–52.PubMedCrossRef
13.
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis, in postmenopausal woman taking alendronate. N Engl J Med. 2008;358:1304–6.PubMedCrossRef
14.
Porrino Jr JA, Kohl CH, Taljanovic M, Rogers LF. Diagnosis of proximal femoral insufficiency fractures in patients receiving biophosphonate therapy. AJR Am J Roentgenol. 2010;194:1061–4.PubMedCrossRef
15.
Bush LA, Chew FS. Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastasis. Radiol Case Rep. 2009;4:1.
16.
Chan SS, Rosenberg ZS, Chan K, et al. Subtrochanteric femoral fractures in patients receiving long term alendronate therapy: imaging features. A JR Am J Roentgenol. 2010;194:1581–6.CrossRef
17.
Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates fur die Beanspruchung der Rohrenknochen. Anat Embryol. 1948;114:1–2.CrossRef
18.
Fleisch H, Neuman WF. Mechanism of calcification: role of collagen polyphosphonates and phosphatase. Am J Physiol. 1961;200:1296–300.
19.
Fleisch H, Bisz S. Isolation from urine of pyrophosphates a calcification inhibitor. Am J Physiol. 1962;203:671–5.PubMed
20.
Fleisch H. In: Bilezikian JP, Rodan GA, editors. Mechanism of action in bisphosphonates in principles of bone biology, vol. 1, 2nd ed. San Diego: Academic Press; 2002. p. 1361–85.
21.
Ott SM. Editorial: long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90(3):1897–9.PubMedCrossRef
22.
Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613–20.PubMedCrossRef
23.
Odvina CV, Zerwekh JE, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.PubMedCrossRef
24.
Lackman SP, Hughee DE, Coxon FB, et al. Nitrogen-containing bisphosphonates inhibit the mevolonate pathways and prevents posttranslational phenylnation of GTPbinding proteins including RAS. J Bone Miner Res. 1998;13:581–9.CrossRef
25.
Weinstein RS, Roberson PK, Manalagas SC. Giant osteoclast formation and long term oral bisphosphonate therapy N Engl J Med 360;1:53–62.
26.
Burr DB, Forwood MR, Fyhrie DP, et al. Perspective: bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. 1997;12:6–15.PubMedCrossRef
27.
Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475–80.PubMedCrossRef
28.
Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate induced osteopetrosis. N Engl J Med. 2003;349:457–63.PubMedCrossRef
Metadata
Title
Atypical diaphyseal femoral fractures—new aspects
Author
Frieda Feldman
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Skeletal Radiology / Issue 1/2012
Print ISSN: 0364-2348
Electronic ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-011-1130-6

Other articles of this Issue 1/2012

Skeletal Radiology 1/2012 Go to the issue

Scientific Article

Automatic radiographic quantification of hand osteoarthritis; accuracy and sensitivity to change in joint space width in a phantom and cadaver study

Meeting Report

Society of Skeletal Radiology 2011 Annual Meeting

Review Article

High resolution imaging of tunnels by magnetic resonance neurography

Case Report

A case of symptomatic cervical perineural (Tarlov) cyst: clinical manifestation and management

Meeting Review

Highlights of the scientific meeting of the 18th Annual Congress of the European Society of Skeletal Radiology (ESSR) 2011

Scientific Article

Neurogenic heterotopic ossification: epidemiology and morphology on conventional radiographs in an early neurological rehabilitation population